Free Trial

Seelos Therapeutics (SEEL) Competitors

Seelos Therapeutics logo
$0.35 0.00 (0.00%)
(As of 12/4/2024 ET)

SEEL vs. BDRX, SRNE, NEXI, PKBO, BLPH, PRFX, TCBP, ONCSQ, TCON, and SMFL

Should you be buying Seelos Therapeutics stock or one of its competitors? The main competitors of Seelos Therapeutics include Biodexa Pharmaceuticals (BDRX), Sorrento Therapeutics (SRNE), NexImmune (NEXI), Peak Bio (PKBO), Bellerophon Therapeutics (BLPH), PainReform (PRFX), TC Biopharm (TCBP), OncoSec Medical (ONCSQ), TRACON Pharmaceuticals (TCON), and Smart for Life (SMFL). These companies are all part of the "pharmaceutical products" industry.

Seelos Therapeutics vs.

Biodexa Pharmaceuticals (NASDAQ:BDRX) and Seelos Therapeutics (NASDAQ:SEEL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, community ranking, media sentiment and dividends.

In the previous week, Biodexa Pharmaceuticals had 1 more articles in the media than Seelos Therapeutics. MarketBeat recorded 1 mentions for Biodexa Pharmaceuticals and 0 mentions for Seelos Therapeutics. Biodexa Pharmaceuticals' average media sentiment score of 0.00 equaled Seelos Therapeutics'average media sentiment score.

Company Overall Sentiment
Biodexa Pharmaceuticals Neutral
Seelos Therapeutics Neutral

17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 23.4% of Seelos Therapeutics shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Comparatively, 1.1% of Seelos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Seelos Therapeutics has a net margin of 203.13% compared to Biodexa Pharmaceuticals' net margin of 0.00%.

Company Net Margins Return on Equity Return on Assets
Biodexa PharmaceuticalsN/A N/A N/A
Seelos Therapeutics 203.13%N/A -431.47%

Biodexa Pharmaceuticals has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, Seelos Therapeutics has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500.

Biodexa Pharmaceuticals has higher earnings, but lower revenue than Seelos Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biodexa Pharmaceuticals$470K1.45-$7.66MN/AN/A
Seelos Therapeutics$2.20M0.06-$37.88MN/AN/A

Seelos Therapeutics received 70 more outperform votes than Biodexa Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Biodexa Pharmaceuticals an outperform vote while only 66.36% of users gave Seelos Therapeutics an outperform vote.

CompanyUnderperformOutperform
Biodexa PharmaceuticalsOutperform Votes
1
100.00%
Underperform Votes
No Votes
Seelos TherapeuticsOutperform Votes
71
66.36%
Underperform Votes
36
33.64%

Biodexa Pharmaceuticals currently has a consensus price target of $200.00, indicating a potential upside of 3,421.13%. Given Biodexa Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Biodexa Pharmaceuticals is more favorable than Seelos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biodexa Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Seelos Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Biodexa Pharmaceuticals beats Seelos Therapeutics on 8 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SEEL vs. The Competition

MetricSeelos TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$130,000.00$6.70B$5.22B$9.17B
Dividend YieldN/A8.02%5.73%4.01%
P/E RatioN/A6.16102.3914.93
Price / Sales0.06327.571,249.9388.11
Price / CashN/A56.9841.6238.06
Price / Book0.005.334.754.94
Net Income-$37.88M$152.05M$119.41M$224.82M
7 Day Performance7.69%7.22%2.52%1.84%
1 Month Performance-49.26%4.06%2.02%9.09%
1 Year Performance-99.81%28.05%31.93%28.53%

Seelos Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SEEL
Seelos Therapeutics
N/A$0.35
flat
N/A-99.9%$130,000.00$2.20M0.0020
BDRX
Biodexa Pharmaceuticals
1.6723 of 5 stars
$5.80
+3.2%
$200.00
+3,348.3%
N/A$690,000.00$83,000.000.0021Gap Down
SRNE
Sorrento Therapeutics
N/A$0.00
-26.7%
N/A-97.4%$606,000.00$62.84M0.00800Gap Down
NEXI
NexImmune
N/A$0.41
0.0%
N/A-92.5%$572,000.00N/A-0.026Gap Down
PKBO
Peak Bio
N/A$0.02
-67.9%
N/A-73.8%$520,000.00$370,000.00-0.143Gap Down
High Trading Volume
BLPH
Bellerophon Therapeutics
0.5065 of 5 stars
$0.04
-27.3%
N/A+17.0%$489,000.00N/A-0.0520Analyst Forecast
Gap Down
PRFX
PainReform
2.9467 of 5 stars
$3.16
+13.7%
$8.00
+153.2%
-75.4%$458,000.00N/A-0.024Gap Up
TCBP
TC Biopharm
0.5248 of 5 stars
$0.56
+0.6%
N/A-99.1%$298,000.00$4.76M0.0041News Coverage
Positive News
Gap Down
ONCSQ
OncoSec Medical
N/A$0.04
+42,300.0%
N/AN/A$253,000.00N/A0.0040Gap Up
High Trading Volume
TCON
TRACON Pharmaceuticals
1.1606 of 5 stars
$0.04
-19.5%
$60.00
+171,328.6%
-99.2%$119,000.00$12.05M0.0120Gap Down
SMFL
Smart for Life
N/A$0.01
-72.9%
N/A-99.9%$67,000.00$11.11M0.00110

Related Companies and Tools


This page (NASDAQ:SEEL) was last updated on 12/5/2024 by MarketBeat.com Staff
From Our Partners